Noxopharm (ASX:NOX) is an Australian-based clinical-stage drug development company with offices in Sydney and New York. Veyonda is the first pipeline drug candidate which is being trialed as a treatment for a broad range of solid tumor cancers and for septic shock. Later generation drug candidates for large markets of unmet medical need such as brain and pancreatic cancer are being developed in an active R&D program. The fully-owned subsidiary, Pharmorage Pty Ltd, was created in 2020 and has a focus on inflammation and autoimmune diseases.Likes and shares are not endorsements

Website: noxopharm.com

Employees: 20 - 49

HQ: 61-2-9144-2223

Location: Gordon, NSW, AU

Revenue: 2.5 - 5 Million

Noxopharm Limited is a leading biotechnology company that focuses on developing innovative medicines for various diseases. If you're looking for contact information for Noxopharm Limited, you've come to the right place. At ConnectPlex.ai, we provide accurate and up-to-date contact information for millions of companies worldwide, including Noxopharm Limited. Our database contains contact details of key decision-makers, executives, and employees of Noxopharm Limited, making it easier for you to connect with the right person and grow your business. Whether you're looking to collaborate, seek investment opportunities, or explore business partnerships, our contact information for Noxopharm Limited will help you get started. Our AI-powered algorithms ensure that our data is accurate, reliable, and updated regularly, so you can trust that you're getting the most current and relevant contact information. With ConnectPlex.ai, you can easily connect with the people who matter most at Noxopharm Limited and take your business to the next level.

Noxopharm Limited is a clinical-stage drug development company based in Australia, with offices in Sydney and New York. The company is focused on developing innovative treatments for a range of solid tumor cancers and septic shock, with their lead pipeline drug candidate, Veyonda, currently in trial. Noxopharm's R&D program is also actively developing later generation drug candidates for large markets of unmet medical need, such as brain and pancreatic cancer. In addition to their drug development efforts, Noxopharm has a fully-owned subsidiary, Pharmorage Pty Ltd, which focuses on inflammation and autoimmune diseases. The company's management team includes experienced industry professionals, including Chief Executive Officer Greg Wyk, Chief Operating Officer Jeanette Bell, and Founder and Managing Director Graham PhD. With a strong focus on research and development, Noxopharm is committed to discovering and developing new therapeutic opportunities to improve the lives of patients around the world.

Noxopharm is a drug development company based in Australia with offices in Sydney and New York. They are working on a drug called Veyonda, which is being tested to treat different types of cancer, including solid tumors and septic shock. They are also working on other drugs for brain and pancreatic cancer. Noxopharm has a subsidiary called Pharmorage that focuses on inflammation and autoimmune diseases. It's important to note that likes and shares on social media do not necessarily mean endorsement.